First targeted gene therapy for Wiskott-Aldrich Syndrome shows promise
12 August 2020
ICH and GOSH researchers have shown the power of gene editing technology CRISPR-Cas9 in correcting DNA ‘spelling mistakes’ that cause rare immune system conditions in children.
The world-leading gene therapy team - pictured above in 2019 - showed for the first time that targeting the delivery of genetic material into a patient’s DNA by inserting the sequence at a precise location could lead to better results for patients with Wiskott-Aldrich syndrome (WAS).
Reported today in Nature Communications, these exciting initial results could lead to a new clinical trial for patients with WAS within 3-4 years. Researchers at GOSH and its research partner the UCL Great Ormond Street Institute of Child Health (ICH) are now applying the targeted gene therapy approach to other immune system conditions, including Severe Combined Immunodeficiency (SCID) and X-linked agammaglobulinemia (XLA).
Wiskott-Aldrich syndrome (WAS)
Children born with severe WAS experience debilitating symptoms including easy bruising, bloody diarrhoea and episodes of prolonged bleeding following nose bleeds or minor trauma. They are more vulnerable to infection and at higher risk of developing certain cancers. Without proper treatment, the condition can be life threatening.
WAS is caused by errors written into a section of DNA known as the X-chromosome, of which males have one copy. Women have two copies, providing a ‘back up’ that makes them much less likely to develop symptoms. WAS therefore affects almost exclusively boys, around 3 in every million worldwide.
The current standard treatment is a bone marrow transplant, but only around 20% of patients are able to find a suitable matching donor. An alternative approach – gene therapy – has shown promise in recent clinical trials.
‘In standard gene therapy, we deliver a corrected version of the DNA into the patient’s cells and it incorporates into their genetic sequence at a random location,’ says Dr Alessia Cavazza, ICH researcher and lead author. ‘This generally works well, as the cell can still ‘read’ the genetic instruction and create the protein it needs. But because the gene isn’t in exactly the right spot, it can cause issues. These range from minor side effects to significant issues or even treatment failure. In this latest study, we wanted to find a better, more precise way of delivering corrected genes.’
A Promising Result
In results published today, the team showed that CRISPR-Cas9 technology – sometimes called ‘molecular scissors’ – can be used to make a physical cut through DNA at the precise place where the WAS gene is usually found. This guided the gene delivery system to slot the corrected gene into the same part of the sequence that it would be in a healthy person.
This precise placement of the WAS gene corrected around 60% of cells, while leaving them otherwise unaffected and able to continue their normal life cycle of maturing into different types of immune system cells.
‘It’s a really promising result,’ says Dr Rajeev Rai, first author of the paper. ‘We showed that using CRISPR to target the therapy corrects a large percentage of patient cells in living tissue, and that the cells are accepted into the bone marrow and behave as they would in a healthy person. The results suggest this technique could be more effective than the standard approach to gene therapy.’
While some gene editing approaches target specific types of DNA spelling mistakes, making them suitable for only select groups of patients, the team’s CRISPR-guided therapy is designed to correct any form of the genetic disease. This means it could benefit any of the 20-25 WAS patients seen at GOSH every year.
In their new home at the Zayed Centre for Research into Rare Disease in Children, the gene therapy team are now planning the next stage of the study - a thorough, long-term test of safety.
“Cutting through human DNA is no simple thing,” says Dr Cavazza. “We are constantly checking and re-checking our results to look for changes to DNA that we did not intend. Thankfully, we found no issues with such ‘off-target effects’ in this study. That’s really important because it’s essential we do not introduce new problems while trying to fix existing ones. We’ll now do even more testing to make sure it will be safe, before we could proceed to a clinical trial with our patients.”
This safety work will be supported by Great Ormond Street Hospital Children’s Charity (GOSH Charity) and LifeArc, through their partnership funding programme aimed at accelerating laboratory research into benefits for patients. If the outcome of this study is positive, the team expect to seek funding for a clinical trial at GOSH within 3-4 years. This would offer patients the chance to benefit from a promising new treatment.
Work that contributed to this study was funded by the NIHR Great Ormond Street Biomedical Research Centre (BRC), GOSH Charity and Sparks. The next stage of the project – translating the approach towards the clinic – will also be supported by funding from GOSH Charity and LifeArc.
- Paper in Nature Communications
- Dr Alessia Cavazza's research profile
- Infection, Immunity and Inflammation Research and Teaching Department, UCL GOS Institute of Child Health
About the UCL Great Ormond Street Institute of Child Health (ICH)
The UCL Great Ormond Street Institute of Child Health (ICH) is part of the Faculty of Population Health Sciences within the School of Life and Medical Sciences at University College London. Together with its clinical partner Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), it forms the UK's only paediatric National Institute for Health Research (NIHR) Biomedical Research Centre and has the largest concentration of children's health research in Europe. For more information visit www.ucl.ac.uk/child-health
About Great Ormond Street Hospital for Children NHS Foundation Trust
Founded in 1852, Great Ormond Street Hospital is one of the world’s leading children’s hospitals with the broadest range of dedicated, children’s healthcare specialists under one roof in the UK. With more than 252,000 outpatient and 43,000 inpatient visits every year, the hospital’s pioneering research and treatment gives hope to children from across the UK with the rarest, most complex and often life-threatening conditions. As an international centre of excellence in child healthcare, our patients and families are central to everything we do – from the moment they come through the door and for as long as they need us. Visit www.gosh.nhs.uk
Research at GOSH is underpinned by support from the National Institute of Health Research (NIHR) Great Ormond Street Hospital Biomedical Research Centre (BRC) and GOSH Charity.
About Great Ormond Street Hospital Children’s Charity
Great Ormond Street Hospital Children’s Charity needs to raise money to support the hospital to give seriously ill children, the best chance for life. The charity funds research into pioneering new treatments for children, provides the most up to date medical equipment, funds support services for children and their families and supports the essential rebuilding and refurbishment of the hospital. You can help us to provide world class care for our patients and families. For more information visit www.gosh.org
About the NIHR
The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:
- Funds, supports and delivers high quality research that benefits the NHS, public health and social care
- Engages and involves patients, carers and the public in order to improve the reach, quality and impact of research
- Attracts, trains and supports the best researchers to tackle the complex health and care challenges of the future
- Invests in world-class infrastructure and a skilled delivery workforce to translate discoveries into improved treatments and services
- Partners with other public funders, charities and industry to maximise the value of research to patients and the economy
The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.